HK1014732A1 - Gp75 as a tumor vaccine for melanoma - Google Patents

Gp75 as a tumor vaccine for melanoma

Info

Publication number
HK1014732A1
HK1014732A1 HK98116009A HK98116009A HK1014732A1 HK 1014732 A1 HK1014732 A1 HK 1014732A1 HK 98116009 A HK98116009 A HK 98116009A HK 98116009 A HK98116009 A HK 98116009A HK 1014732 A1 HK1014732 A1 HK 1014732A1
Authority
HK
Hong Kong
Prior art keywords
fragment
stimulating
vaccines
amino acid
nucleic acid
Prior art date
Application number
HK98116009A
Other languages
English (en)
Inventor
Alan N Houghton
Setaluri Vijayasaradhi
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23976841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1014732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of HK1014732A1 publication Critical patent/HK1014732A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98116009A 1990-03-22 1998-12-28 Gp75 as a tumor vaccine for melanoma HK1014732A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49743190A 1990-03-22 1990-03-22
PCT/US1991/001942 WO1991014775A1 (fr) 1990-03-22 1991-03-22 Utilisation de gp75 comme vaccin tumoral contre les melanomes

Publications (1)

Publication Number Publication Date
HK1014732A1 true HK1014732A1 (en) 1999-09-30

Family

ID=23976841

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98116009A HK1014732A1 (en) 1990-03-22 1998-12-28 Gp75 as a tumor vaccine for melanoma

Country Status (21)

Country Link
US (2) US6168946B1 (fr)
EP (2) EP0522078B1 (fr)
JP (2) JP3336006B2 (fr)
AT (1) ATE187493T1 (fr)
AU (1) AU660412B2 (fr)
CA (1) CA2078773C (fr)
CZ (1) CZ290278B6 (fr)
DE (1) DE69131829T2 (fr)
DK (1) DK0522078T3 (fr)
ES (1) ES2141089T3 (fr)
FI (1) FI113786B (fr)
GR (1) GR3032804T3 (fr)
HK (1) HK1014732A1 (fr)
HU (1) HU218416B (fr)
IE (2) IE20000918A1 (fr)
NO (1) NO311366B1 (fr)
NZ (1) NZ237532A (fr)
PL (3) PL168235B1 (fr)
PT (1) PT97103B (fr)
SK (1) SK282873B6 (fr)
WO (1) WO1991014775A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
US7041801B1 (en) * 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US7015312B1 (en) 1996-02-09 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US20030157720A1 (en) * 2002-02-06 2003-08-21 Expression Technologies Inc. Protein standard for estimating size and mass
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4808704A (en) * 1981-09-30 1989-02-28 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human malignant melanoma
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5009495A (en) * 1989-05-26 1991-04-23 Williams Robert D Hinge for eyeglasses
DE69033842T2 (de) 1989-08-04 2002-06-20 Schering Ag Äusserliche domäne von c-erbb-2:gp75
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
US5262117A (en) * 1990-10-12 1993-11-16 Centro Sviluppo Settori Impiego S.R.L. Process for preparing thermoinsulating and/or structural formed articles and products so obtained
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin

Also Published As

Publication number Publication date
PL169168B1 (pl) 1996-06-28
EP0522078A4 (en) 1993-05-26
PT97103B (pt) 1999-02-26
JP3336006B2 (ja) 2002-10-21
ATE187493T1 (de) 1999-12-15
NO923659D0 (no) 1992-09-21
IE20000918A1 (en) 2001-05-30
US20050037462A1 (en) 2005-02-17
DK0522078T3 (da) 2000-06-13
FI924222A (fi) 1992-09-21
PT97103A (pt) 1991-12-31
NZ237532A (en) 1993-03-26
AU660412B2 (en) 1995-06-29
PL169105B1 (pl) 1996-06-28
CZ290278B6 (cs) 2002-07-17
HU218416B (hu) 2000-08-28
EP0965640A1 (fr) 1999-12-22
ES2141089T3 (es) 2000-03-16
GR3032804T3 (en) 2000-06-30
WO1991014775A1 (fr) 1991-10-03
US6168946B1 (en) 2001-01-02
JP2002241314A (ja) 2002-08-28
CS76091A3 (en) 1992-02-19
CA2078773C (fr) 2001-07-03
AU7690691A (en) 1991-10-21
EP0522078B1 (fr) 1999-12-08
HUT62934A (en) 1993-06-28
SK282873B6 (sk) 2003-01-09
FI924222A0 (fi) 1992-09-21
IE910820A1 (en) 1991-09-25
PL168235B1 (pl) 1996-01-31
NO923659L (no) 1992-11-06
CA2078773A1 (fr) 1991-09-23
FI113786B (fi) 2004-06-15
EP0522078A1 (fr) 1993-01-13
PL289550A1 (en) 1992-07-27
DE69131829T2 (de) 2000-06-15
DE69131829D1 (de) 2000-01-13
NO311366B1 (no) 2001-11-19
JPH06501837A (ja) 1994-03-03

Similar Documents

Publication Publication Date Title
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
GR3032804T3 (en) Gp75 as a tumor vaccine for melanoma.
IL144371A0 (en) Her-2/neu fusion proteins
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
NZ314058A (en) Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
FI98217B (fi) Menetelmä nekroositekijän valmistamiseksi
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DK0458878T3 (da) Nyt monoklonalt antistof mod et nyt antigen, der er associeret med humane tumorer
HUP9901254A2 (hu) Nemdendrites szerkezetű gerincet alkotó peptid hordozó
NO975730L (no) Metode for ökning av beskyttende immunresponser
EP0719150A4 (fr) Vaccin cellulaire et procedes d'utilisation dans le traitement de tumeurs malignes solides
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
WO1999065517A3 (fr) Compositions therapeutiques produisant une reponse immunitaire par renouvellement des antigenes
CA2254082A1 (fr) Vaccin contre le cancer recto-colique metastatique
CA2440610A1 (fr) Induction de l'immunite tumorale par des variantes de la proteine de fixation a folate
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
RU2003107017A (ru) Копозиции и способы терапии и диагностики злокачественных опухолей, связанных с her-2/neu
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060322